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Introduction
Several clinical and epidemiological studies have suggested
that hyperhomocysteinemia is an independent risk factor for
premature cerebral stroke, peripheral and vascular diseases
(e.g. vasoconstrictive diseases, infarction, ischemia) [1–6].
Patients with these pathologies show plasma homocysteine
levels higher than normal (Table 1).
There is increasing evidence that hyperhomocysteinemia
may affect the coagulation system and the resistance of
endothelium to thrombosis and that it may interfere with the
vasodilator and antithrombotic functions of nitric oxide.
Elevated plasma homocysteine may pose an oxidative stress,
leading to the development of vascular damage through both
direct and indirect pathways [7]. In fact, antioxidant plasmatic
capacity shows a positive correlation with homocysteine plas-
ma levels. Moreover, this factor is correlated with the produc-
tion of endothelial nitric oxide, a factor of vasculopathic risk
and, at the same time, involved in migraine pathogenesis [8].
Some authors [9–13] have found the existence of an epi-
demiological correlation between an increased risk of cere-
brovascular disease and migraine with aura. The hypothesis
is that ischemia is caused by an alteration of specific coagu-
lation factors, such as antiphospholipid antibodies (aPLs),
circulating immunoglobulins with prothrombotic effect
[14]. Moreover, in migraine subjects a prevalence of elevat-
ed levels of lipoprotein A (>300 mg/l) was found with no
significant difference between patients with and without
aura [15].
Homocysteine plasma levels after methionine oral load-
ing (100 mg/kg) may help identify alterations in methionine
metabolism, also in subjects with normal homocysteine
plasma levels at baseline, and may predict a higher vascular
disease frequency in migraneous patients, in particular with
aura [16].
Boushey et al. [17] showed, in a meta-analysis of 27
studies, that post-methionine load and fasting hyperhomo-
cysteinemia are independent of each other in the majority of
individuals, and that without methionine loading 27%–40%
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Abstract Clinical studies suggest
that hyperhomocysteinemia could be
considered an independent risk factor
for premature cerebral, peripheral
and vascular diseases. A number of
authors found an epidemiological
correlation between increased risk of
cerebrovascular disease and migraine
with aura. In this study, 34 patients
suffering from migraine with aura
and 36 healthy controls were evalu-
ated with respect to total plasma
homocysteine levels, measured with
FPIA immunoassay in the fasting
state and after methionine load.
Moreover, vitamin B12, folate and
other classic biochemical indicators
of atherosclerosis disease were eval-
uated. In this study, homocysteine
levels, both at basal and after load,
and other cardiovascular risk factors
such as vitamin B12 and apo-LpA
were within the normal range. Other
multicentric randomised trials are
needed to carry on and confirm these
data.
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Table 1 Causes of hyperhomocysteinemia
Inherited
Methylene tetrahydrofolate reductase deficiency
Cystathionine b-synthase deficiency
Cobalamine reductase deficiency
Methyltransferase and cobalamine reductase deficiencies
Cystathioninase deficiency
Methionine synthase defect
Cobalamine transport defect
Efflux lysosomal syndrome
Acquired
Demographics: age / sex (> age, male, menopause)
Medications
Folate antagonists (methotrexate, anticonvulsants, isoniazide)
Vitamin B6 antagonists (theophylline)
Chronic diseases
Endocrine (hypothyroidism)
Other diseases (chronic renal failure, psoriasis, heart and other organ transplantations)
Malignancies: ovary, pancreas, lung cancer; acute lymphoblastic leukemia
Vitamin deficiencies: folic acid, vitamin B6, vitamin B12
Lifestyle: smoking, excess of alcohol and coffee intake, lack of exercise
Fig. 1 Homocysteine metabolism
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of the cases of elevated plasma homocysteine could be
missed. Hyperhomocysteinemia can be caused by genetic
defects (relative or absolute decreases in the enzymes dri-
ving the biochemical reactions) or nutritional deficiencies as
reported in Table 1.
Homocysteine is an intermediate amino acid formed dur-
ing the metabolism of methionine, an essential sulfur-con-
taining amino acid supplied from dietary proteins. A large
complex of enzymes and cofactors (vitamin B12, B6 and
folate) is necessary to maintain homocysteine at normal
serum levels (Fig. 1).
In this study we evaluated the homocysteine levels in
patients suffering from migraine with aura and in normal
subjects, to detect possible alterations of homocysteine plas-
ma levels at basal time and after methionine oral load. At the
same time, we collected information about “classic” plas-
matic markers of cardiovascular risk.
Materials and methods
Patients and controls
We recruited 34 migraine patients (Table 2), evaluated in the
intercritical period, 12 men and 22 women, aged 18–60 years
(mean, 37.8 years; SD=11.8 years) from the Headache Center at
our hospital; 6% of patients were smokers. The mean body mass
index was 24.28 kg/m2 (SD=4.32 kg/m2). Mean blood pressure
was 127±18 mmHg (systolic) and 83±12 mmHg (diastolic). 18%
of patient’s relatives referred migraine (5% with aura) and only
10% of women assumed oral contraceptives. The diagnosis of
migraine with aura (MwA) was performed according to the
International Headache Society (IHS) classification [20]. The fre-
quency of attacks ranged between 3 and 20 per year, with an aver-
age of 5 attacks/year.
A total of 36 healthy age- and sex-matched volunteers com-
prised the control group (11 men and 25 women); mean age was
42.1 years (SD=12.6 years).
Biochemical data
Total plasma homocysteine levels were measured with FPIA
immunoassay (Imx Abbott Analyzer) both in the fasting state
(baseline, time 0) and after methionine load (4 h) [21–23]. Hyper-
homocysteinemia 2–8 h after an oral methionine load (standard
dose, 0.1 g/kg body weight of L-methionine mixed in fruit juice)
may identify individuals at increased risk for vascular disease
despite normal fasting total plasma homocysteine concentrations
(an additional 27% of at-risk cases).
Hyperhomocysteinemia is usually defined by using an arbi-
trary cut-off; normal plasma homocysteine levels range from 5 to
13 µmol/l. Men have higher concentrations of homocysteine than
women (1 µmol/l), and amounts of homocysteine tend to increase
slightly with age [24].
Clinical information was obtained by a direct interview from
all the patients responding to questionnaire items on other risk fac-
tors: body mass index (BMI), cardiovascular disease, hypertension
(basal blood pressure, BP), diabetes mellitus, smoking, familiar
history of premature cardiovascular disease or migraine, and actu-
al use of medication (e.g. oral contraceptives) (Table 2).
In addition to the classic lipid levels (total cholesterol, HDL-
cholesterol, LDL-cholesterol, triglycerides), we also evaluated
other risk factors for atherosclerosis, such as apolipoproteins A1
and B, fibrinogen, vitamin B12 and folate. These have a significant
role as nutrients which impact on homocysteine metabolism.
Statistical analysis
Data were analysed using the t test, and are expressed as mean and
standard deviation in tables and text.
Table 2 Characteristics of patients and controls
Age, Smoking BMI, Systolic Diastolic Familiarity, nb Oral
yearsa habit, n kg/m2 a blood pressure blood contraceptives
>145 mmHg, pressure use, n
n >95 mmHg, n
Migraine 37.79 (11.82) 4 24.28 (4.32) 3 4 7 3
with aura
(n=34)
Controls (n=36) 42.1 (12.6) 3 25.54 (5.37) 2 1 6 4
a Values are expressed as mean (SD)
b Parents and first-degree relatives for stroke and myocardial infarction
BMI, body mass index
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Results
A baseline homocysteine level higher than 13 µmol/l (<13
under 60 years, <20 over 60) or a pathological difference
between the basal value and the post-load value (>27
µmol/l) is considered an indicator of high risk for cardiovas-
cular disease. In Table 3, we report the homocysteine data of
our patients.
The others plasmatic parameters of cardiovascular risk
are reported in Table 4.
Discussion
Although there is evidence from epidemiological studies sup-
porting a positive relationship between elevated plasma
homocysteine and coronary heart disease, and between
migraine and stroke (in women, under 45 years of age [11,
12]), these studies are inconsistent and not univocal, because
of differences in study design, methodological or statistical
power and chance (publication bias) [2]. It remains to be
demonstrated that reducing elevated plasma homocysteine
levels will result in a reduction in the risk for cardiovascular
disease. Moreover, the definition of elevated homocysteine
levels is not standardized, and substantial differences exist in
the “normal” reference used in the literature (day-to-day, post-
prandial, orthostatic, intra- and inter-individual variations).
In this study, despite the small series, we found no sig-
nificant difference between migraine with aura patients and
controls with respect to episodes of stroke or other vascular
diseases. Only in one case was homocysteine over the nor-
mal range. The patient was a 45-year-old woman suffering
from migraine with prolonged aura, with a familial history
of migraine and diabetes mellitus, but not for myocardial
infarction or stroke. Her lifestyle was free from alcohol and
tobacco smoke, dietary intake was correct, and neuroimag-
ing results were normal.
There are reports suggesting that vitamins are related to
progression of atherosclerosis and variation of circulating
homocysteine [17, 18]. Therefore, the use of folic acid, vitamin
B6 and B12 supplementation was proposed to normalize the
pathologically high homocysteine levels, although there is no
clear evidence that treatment with vitamins alters progression
of atherosclerosis or reduces cardiovascular events [17–19].
In our study homocysteine levels and other cardiovascu-
lar risk factors such as vitamin B12 and apo-LpA were with-
in the normal ranges and were not related to the presence of
migraine with aura. Although this study shows a negative
relationship between migraine with aura and homocysteine,
in the literature there are some reports referring these corre-
lations. The association between homocysteine levels and
migraine is less documented than that between migraine and
stroke. Therefore, careful multicentric randomized trials
with a large number of patients are needed to establish
whether migraine with aura may be associated with a sig-
nificant risk for cardiovascular disease and, in case of posi-
tive results, to define the prognostic and predictive values of
serum homocysteine in these patients. In conclusion, lack-
ing positive evidence, this test has no pathognomonic indi-
cation in patients suffering from migraine with aura.
Table 3 Homocysteine plasma levels in migraine patients and controls. Values are mean (SD) expressed in micromolar
Baseline Post-load
Migraine with aura 11.08 (3.57) 30.32 (9.27)
Controls 12.8 (6.01) 31.05 (7.42)
p NS NS
NS, not significant
Table 4 Plasmatic cardiovascular risk factors in patients and controls. Values are mean (SD). Two patients and two controls were aged over
60 years. Both patients’ and control’s biochemical parameters fell into the normal ranges
B12, Folate, ApoA, ApoB, CHOL, HDL, LDL, TRIG, Fibrin,
pg/ml ng/dl mg/dl mg/dl mg/dl mg/dl mg/dl mg/dl mg/dl
Controls 350 (143) 8.0 (4.5) 107.0 (34.4) 105.0 (32.6) 194 (48) 64.0 (18.3) 130 (45.3) 118 (48.6) 315 (31.4)
Migraine 374.4 (194.1) 5.93 (3.37) 112.6 (28.21) 93.5 (27.2) 206.7 (38.9) 54.7 (13.4) 119 (39.7) 94.5 (40.3) 278.9 (41.0)
with aura
CHOL, cholesterol; TRIG, triglycerides
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